Pds biotech achieves safety requirement milestone for the first 12 patients in the versatile-002 phase 2 combination trial of pds0101-keytruda® in advanced head and neck cancer

No dose limiting toxicities observed in initial group of 12 patients no dose limiting toxicities observed in initial group of 12 patients

PDSB Ratings Summary

PDSB Quant Ranking